Apitope, a clinical stage biotech company, has named Dr William Jenkins as its independent, non-executive director, it was reported yesterday. Dr Jenkins has a wealth of pharmaceutical industry experience following a 30-year career in clinical medicine and research. He has also served on several boards including Ablynx, Evotec and Acambis.
Stephane Verdood, chairman of the board, said, 'We are pleased to welcome William to Apitope's board of directors. William's extensive drug development expertise is a valuable addition as we seek to advance development of our potential first-in-class antigen-specific treatments targeted at autoimmune diseases. William has advised companies through various stages of growth to maturity and I know he will provide further strength and depth to the board.'
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial
Biosenic finalises agreement with Phebra for oral arsenic troxide development
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Allorion Therapeutics signs exclusive option and global license agreement with AstraZeneca